ReviewSeminars in cancer biology2011
Gene signatures in hepatocellular carcinoma (HCC).
Review in Seminars in cancer biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 63 citations in OpenAlex.
- Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER.Nature genetics · 2025Article
- Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.Cell reports. Medicine · 2024Review
- Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer.Life science alliance · 2023Article
- PAIP1 is a novel oncogene in human hepatocellular carcinoma.Discover oncology · 2022Article
- M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.BMC cancer · 2022Article
- Chronic alcohol exposure induces hepatocyte damage by inducing oxidative stress, SATB2 and stem cell-like characteristics, and activating lipogenesis.Journal of cellular and molecular medicine · 2022Article
- Complex roles of nicotinamide N-methyltransferase in cancer progression.Cell death & disease · 2022Review
- Current Advances in RNA Therapeutics for Human Diseases.International journal of molecular sciences · 2022Review
- A Cell Cycle-Related 13-mRNA Signature to Predict Prognosis in Hepatocellular Carcinoma.Frontiers in oncology · 2022Article
- Transcription Control of Liver Development.Cells · 2021Review
- Bookmarking by Non-pioneer Transcription Factors during Liver Development Establishes Competence for Future Gene Activation.Cell reports · 2020Article
- Identification of potential hub genes related to the progression and prognosis of hepatocellular carcinoma through integrated bioinformatics analysis.Oncology reports · 2020Article
- Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.Cell cycle (Georgetown, Tex.) · 2019Article
- MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.Neoplasia (New York, N.Y.) · 2019Article
- Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma.Royal Society open science · 2018Article
- Integrative genomic analysis of mouse and human hepatocellular carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Preclinical models of non-alcoholic fatty liver disease.Journal of hepatology · 2018Review
- MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study.FEBS open bio · 2017Article
- Investigating genetic characteristics of hepatitis B virus-associated and -non-associated hepatocellular carcinoma.Genetics research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Primary hepatocellular carcinoma (HCC) is a significant human cancer globally, with poor prognosis. New and efficacious therapy strategies are needed as well as new biomarkers for early detection of at-risk patients. In this review, we discuss select microarray studies of human HCCs, and propose a gene signature that has promise for clinical/translational application. This gene signature combines the proliferation cluster of genes and the hepatic cancer initiating/stem cell gene cluster for identification of HCCs with poor prognosis. Evidence from cell-based assays identifies the existence of a mechanistic link between these two gene clusters, involving the proliferation cluster gene polo-like kinase 1 (PLK1). We propose that PLK1 is a promising therapy target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.